Premium
High‐dose Cepharanthin for pediatric chronic immune thrombocytopenia in Japan
Author(s) -
Yamazaki Taro,
Shibuya Atsushi,
Ishii Saori,
Miura Nobuyuki,
Ohtake Akira,
Sasaki Nozomu,
Araki Ryuichiro,
Ota Yatio,
Fujiwara Mitsuhiro,
Miyajima Yuji,
Uetake Kimiaki,
Hamahata Keigo,
Kato Koji,
Kawakami Kiyoshi,
Toyoda Hidemi,
Moriguchi Naohiko,
Okada Masahiko,
Nishi Masanori,
Ogata Yoshiyasu,
Takimoto Tomohito,
Ohga Shouichi,
Ohta Shigeru,
Amemiya Shin
Publication year - 2017
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.13151
Subject(s) - medicine , immune thrombocytopenia , adverse effect , gastroenterology , observational study , multicenter study , platelet , pediatrics , randomized controlled trial
Background A nationwide, multicenter and observational study was retrospectively conducted to evaluate the clinical utility of Cepharanthin ( CEP ) for pediatric patients with chronic immune thrombocytopenia ( ITP ). Methods Clinical and laboratory data for 46 Japanese patients aged <16 years who were diagnosed as having chronic ITP in 14 hospitals during 2001–2011, and were treated with CEP for >12 months, were analyzed. Results Median daily CEP dose was 1 mg/kg (range, 0.12–2 mg/kg). Median platelet count prior to CEP was 20.5 × 10 9 /L ( IQR , 8.3–53.0 × 10 9 /L), and then significantly increased to 58.5 × 10 9 /L ( IQR , 22.8–115.0 × 10 9 /L) and 69.0 × 10 9 /L ( IQR , 23.0–134.0 × 10 9 /L) at 12 and 24 months of treatment, respectively. No life‐threatening bleeds or moderate–severe adverse events were reported. Of 38 patients who received both corticosteroids ( CS ) and CEP , 17 patients (45%) were weaned from CS , and 15 patients (39%) attained the reduced dose of CS . The duration from the start of CEP to the stopping of CS was a median of 413 days (range, 49–1734 days) in patients who were weaned from CS . Conclusions CEP alone or combined with CS was useful for the management of pediatric chronic ITPs.